JPM26: Integra restarts by fixing supply and taking advantage of tailwinds in reimbursement
Integra LifeSciences used its update at the ongoing 2026 JP Morgan Healthcare Conference in San Francisco to frame 2025 and 2026 as a deliberate transition period. The company described a shift from disruption and remediation toward more predictable execution, supported by product relaunches, a more resilient supply chain and reimbursement changes that could make parts…